AD02P3

AD02P3 is a preclinical anti-infective candidate being developed by Andira Medicine (also referred to as Andira Pharmaceuticals) for the treatment of vancomycin-resistant enterococcal (VRE) and other severe antibiotic-resistant bacterial infections.[1][5][7] It is positioned as an adjunctive agent designed to restore or enhance the activity of existing antibiotics, particularly daptomycin, by eliminating or overcoming bacterial resistance mechanisms, thereby extending the clinical utility of last-line agents against multidrug-resistant Gram-positive pathogens.[5][7] Detailed molecular target, chemical class, and pharmacology have not been publicly disclosed, but the program is described by the company as a breakthrough therapeutic approach for deadly antibiotic-resistant infections, with ongoing preclinical development and patent protection in the United States.[1][7]